SG160195A1 - N-phenyl-2-pyrimidine-amine derivatives - Google Patents

N-phenyl-2-pyrimidine-amine derivatives

Info

Publication number
SG160195A1
SG160195A1 SG200605266-6A SG2006052666A SG160195A1 SG 160195 A1 SG160195 A1 SG 160195A1 SG 2006052666 A SG2006052666 A SG 2006052666A SG 160195 A1 SG160195 A1 SG 160195A1
Authority
SG
Singapore
Prior art keywords
pyrimidine
phenyl
amine derivatives
methyl
formula
Prior art date
Application number
SG200605266-6A
Other languages
English (en)
Inventor
Olivier Loiseleur
Daniel Kaufmann
Stephan Abel
Hans Michael Buerger
Mark Meisenbach
Beat Schmitz
Gottfried Sedelmeier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG160195A1 publication Critical patent/SG160195A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200605266-6A 2002-02-07 2003-02-06 N-phenyl-2-pyrimidine-amine derivatives SG160195A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202873.6A GB0202873D0 (en) 2002-02-07 2002-02-07 Organic compounds

Publications (1)

Publication Number Publication Date
SG160195A1 true SG160195A1 (en) 2010-04-29

Family

ID=9930607

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200605266-6A SG160195A1 (en) 2002-02-07 2003-02-06 N-phenyl-2-pyrimidine-amine derivatives

Country Status (26)

Country Link
US (8) US7456283B2 (es)
EP (2) EP1474408B1 (es)
JP (2) JP4653954B2 (es)
KR (1) KR101027044B1 (es)
CN (2) CN100347162C (es)
AU (1) AU2003244444B2 (es)
BR (2) BRPI0307529B1 (es)
CA (2) CA2737565C (es)
CO (1) CO5601018A2 (es)
CY (2) CY1112938T1 (es)
DK (2) DK1474408T3 (es)
EC (2) ECSP045220A (es)
ES (2) ES2384872T3 (es)
GB (1) GB0202873D0 (es)
HK (2) HK1145322A1 (es)
IL (3) IL163158A (es)
MX (1) MXPA04007642A (es)
NO (2) NO327366B1 (es)
NZ (3) NZ569731A (es)
PL (1) PL209475B1 (es)
PT (2) PT2248807E (es)
RU (2) RU2370493C2 (es)
SG (1) SG160195A1 (es)
SI (2) SI1474408T1 (es)
WO (1) WO2003066613A1 (es)
ZA (1) ZA200405970B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2004108699A1 (en) * 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
MXPA05013349A (es) * 2003-06-13 2006-03-09 Novartis Ag Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
PL2068938T3 (pl) 2006-09-22 2011-06-30 Novartis Ag Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US20080103305A1 (en) * 2006-10-26 2008-05-01 Macdonald Peter Process for the preparation of imatinib
BRPI0718812A2 (pt) * 2006-11-16 2013-12-03 Italiana Sint Spa Processo para a preparação de imatinib e intermediários deste
CN100451015C (zh) * 2007-02-14 2009-01-14 杭州盛美医药科技开发有限公司 一种伊马替尼的制备方法
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
WO2009080366A1 (en) * 2007-12-22 2009-07-02 Synthon B.V. A process of making imatinib
CN101497601B (zh) * 2008-01-29 2012-11-07 福建南方制药股份有限公司 伊马替尼的合成方法
PL215042B1 (pl) * 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania imatinibu
KR20100021321A (ko) * 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
US8697702B2 (en) 2008-12-01 2014-04-15 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CN101654416B (zh) * 2009-09-16 2013-06-05 成都神黄医药科技开发有限公司 N-[3-硝基-4-甲基-苯基]-4-醛基-苯甲酰胺及其制备方法以及其衍生物的制备方法
US20110306763A1 (en) 2009-12-10 2011-12-15 Shanghai Parling Pharmatech Co., Ltd. Process for the preparation of imatinib and salts thereof
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011130918A1 (zh) * 2010-04-23 2011-10-27 上海百灵医药科技有限公司 一种伊马替尼的合成方法
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
TR201007005A2 (tr) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. İmatinib baz üretim yöntemi
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
CN102827144A (zh) * 2012-09-05 2012-12-19 湖南欧亚生物有限公司 一种伊马替尼的制备方法
RU2537398C1 (ru) * 2013-08-20 2015-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный технологический университет" (СибГТУ) Гексазамещенные пара-аминофенолы с ариламидными группами в 2,6-положениях по отношению к гидроксилу
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
JP6691971B2 (ja) 2016-10-17 2020-05-13 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 慢性骨髄性白血病を治療又は寛解するための医薬組成物
PL3539138T3 (pl) 2016-11-11 2021-12-13 Curium Us Llc Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych
EP3333162A1 (en) 2016-12-12 2018-06-13 Silesian Catalysts sp. z o.o. Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
SG11202003463XA (en) 2017-10-18 2020-05-28 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as PRMT5 inhibitors
CN108164505B (zh) * 2018-01-16 2020-11-03 扬州大学 一种伊马替尼的合成方法
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE531480C (de) * 1929-07-03 1931-08-10 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Aryliden einer unsymmetrischen o-Xylenolcarbonsaeure
US2808433A (en) * 1953-08-21 1957-10-01 Du Pont Benzene dicarboxylic acid derivatives
GB862127A (en) * 1958-07-04 1961-03-01 Ici Ltd Derivatives of 2-hydroxy-3-naphthanilide
US3505433A (en) * 1965-03-08 1970-04-07 Hooker Chemical Corp 2-haloperfluoro-1-cycloalken-1-ylphosphoryl compounds
US3505389A (en) * 1966-08-18 1970-04-07 Hooker Chemical Corp 4-amino-2,3,5,6-tetrachlorobenzoic acid and derivatives thereof
US3505398A (en) 1966-09-22 1970-04-07 Standard Oil Co Terephthalic acid crystallization
US3763234A (en) * 1970-12-03 1973-10-02 Halcon International Inc Preparation of amides
JPS4987761U (es) 1972-11-17 1974-07-30
JPS563375B2 (es) * 1972-12-25 1981-01-24
JPS5720923B2 (es) * 1974-04-02 1982-05-04
US4281000A (en) * 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
JPS5665804A (en) * 1979-11-01 1981-06-03 Ishihara Sangyo Kaisha Ltd Control agent against injurious organism
DE3305755A1 (de) 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
NZ219974A (en) 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
JP2894804B2 (ja) * 1989-07-19 1999-05-24 武田薬品工業株式会社 ２―アミノ―５―メチルベンゾフェノン類及びその製造法
JPH03130252U (es) 1990-04-11 1991-12-27
FR2664895B1 (fr) * 1990-07-20 1992-10-30 Theramex Laboratoire Nouveaux derives de la 6-methyl 19-nor progesterone, substitues en 3 et leur procede d'obtention.
DE4110483A1 (de) * 1991-03-30 1992-10-01 Bayer Ag Substituierte salicylamide, mittel gegen pflanzenkrankheiten
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
FR2689925B1 (fr) 1992-04-08 1994-05-27 Valeo Securite Habitacle Dispositif de verrouillage d'une serrure dans son support.
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
DE4428380A1 (de) * 1994-08-11 1996-02-15 Bayer Ag 4-Trifluormethylbenzamide
JPH0987761A (ja) 1995-09-22 1997-03-31 Nikko Kinzoku Kk 銅転炉スラグからの銅の回収方法
JP3130252B2 (ja) 1996-07-12 2001-01-31 小糸工業株式会社 座席のヘッドレスト装置
EP0994875B1 (en) * 1997-06-30 2004-03-10 Targacept, Inc. 3-pyridyl-1-azabicycloalkane derivatives for prevention and treatment of cns disorders
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6579872B1 (en) * 1998-05-15 2003-06-17 Astrazeneca Ab Bezamide derivatives for the treatment of diseases mediated by cytokines
EP1115707B1 (en) 1998-09-25 2003-11-12 AstraZeneca AB Benzamide derivatives and ther use as cytokine inhibitors
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CA2474738C (en) 2011-10-04
DK2248807T3 (da) 2013-08-26
KR101027044B1 (ko) 2011-04-11
EP1474408B1 (en) 2012-05-23
NZ554430A (en) 2008-08-29
EP2248807A1 (en) 2010-11-10
ES2384872T3 (es) 2012-07-13
PL209475B1 (pl) 2011-09-30
JP2005528340A (ja) 2005-09-22
PT1474408E (pt) 2012-07-25
ECSP045220A (es) 2004-09-28
KR20040081154A (ko) 2004-09-20
US20070293683A1 (en) 2007-12-20
IL189658A (en) 2011-05-31
HK1070893A1 (es) 2005-06-30
NZ534315A (en) 2007-06-29
ZA200405970B (en) 2006-05-31
US7825247B2 (en) 2010-11-02
US20070293673A1 (en) 2007-12-20
CA2737565A1 (en) 2003-08-14
GB0202873D0 (en) 2002-03-27
US7579467B2 (en) 2009-08-25
IL189657A (en) 2010-12-30
CY1112938T1 (el) 2016-04-13
HK1145322A1 (es) 2011-04-15
EP2248807B1 (en) 2013-07-03
IL189657A0 (en) 2008-06-05
PL371197A1 (en) 2005-06-13
US20060142580A1 (en) 2006-06-29
CA2737565C (en) 2013-04-09
NO20091976L (no) 2004-11-05
CN101016262A (zh) 2007-08-15
US7456283B2 (en) 2008-11-25
AU2003244444B2 (en) 2007-08-09
SI1474408T1 (sl) 2012-07-31
JP4653954B2 (ja) 2011-03-16
RU2370493C2 (ru) 2009-10-20
BRPI0307529B1 (pt) 2018-01-30
EP1474408A1 (en) 2004-11-10
AU2003244444A1 (en) 2003-09-02
ECSP095220A (es) 2009-08-28
US20090137805A1 (en) 2009-05-28
CO5601018A2 (es) 2006-01-31
CN100347162C (zh) 2007-11-07
CA2474738A1 (en) 2003-08-14
PT2248807E (pt) 2013-09-02
US20120226039A1 (en) 2012-09-06
AU2003244444B9 (en) 2003-09-02
US20070293504A1 (en) 2007-12-20
US7816359B2 (en) 2010-10-19
DK1474408T3 (da) 2012-06-25
BR0307529A (pt) 2004-12-21
NO327366B1 (no) 2009-06-15
MXPA04007642A (es) 2004-11-10
CY1114351T1 (el) 2016-08-31
IL163158A (en) 2010-11-30
NO20043685L (no) 2004-11-05
CN1630648A (zh) 2005-06-22
JP2010138194A (ja) 2010-06-24
ES2425980T3 (es) 2013-10-18
IL189658A0 (en) 2008-06-05
RU2004126941A (ru) 2005-10-10
US20070293672A1 (en) 2007-12-20
SI2248807T1 (sl) 2013-10-30
US20150018552A1 (en) 2015-01-15
NZ569731A (en) 2009-11-27
RU2007148217A (ru) 2009-07-10
WO2003066613A1 (en) 2003-08-14
US9573928B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
SG160195A1 (en) N-phenyl-2-pyrimidine-amine derivatives
HK1069395A1 (en) Phthalazinone derivatives 2,3
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
WO2004013120A8 (en) Novel benzodioxoles
NZ536734A (en) Spiroindolinepiperidine derivatives
MY146532A (en) Thiazole derivative
MY177250A (en) Novel nicotinamide derivative or salt thereof
MX337516B (es) Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer.
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
IL189069A0 (en) Piperidine and piperazine derivatives as p2x3 antagonists
TN2009000024A1 (en) Prodrug of cinnamide compound
WO2008136444A1 (ja) 縮合複素環誘導体
TW200503712A (en) (2-carboxamido)(3-amino)thiophene compounds
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
TW200609223A (en) Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives
GB0401336D0 (en) Organic compounds
EP1656127A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
TW200602331A (en) Process for preparing thiazole compound
EP1357124A4 (en) HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS
WO2007070865A3 (en) Piperazine compounds as agonists of trpv4 channel receptors
WO2003028732A1 (fr) Antagoniste de recepteur
UA89940C2 (en) 3-phenylpropionic acid derivatives
JO2307B1 (en) Papermidine derivatives